Land: Bandaríkin
Tungumál: enska
Heimild: NLM (National Library of Medicine)
CLOTRIMAZOLE (UNII: G07GZ97H65) (CLOTRIMAZOLE - UNII:G07GZ97H65)
Cardinal Health
ORAL
PRESCRIPTION DRUG
Clotrimazole is indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment. Clotrimazole is also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION.) Clotrimazole is contraindicated in patients who are hypersensitive to any of its components. No data available.
Clotrimazole Troche (lozenges) USP 10 mg troche is supplied as white, round, flat face beveled edge troche with product identification “54 552” on one side and plain on the other side. Overbagged with 10 tablets per bag, NDC 55154-4951-0 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Avoid freezing. Distr. by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724 Distributed By: Cardinal Health Dublin, OH 43017 L37410140518 10001777/09 Revised April 2016
Abbreviated New Drug Application
CLOTRIMAZOLE- CLOTRIMAZOLE LOZENGE CARDINAL HEALTH ---------- CLOTRIMAZOLE TROCHE(LOZENGES) USP FOR TOPICAL ORAL ADMINISTRATION RX ONLY DESCRIPTION Each Clotrimazole Troche (lozenge) USP contains 10 mg clotrimazole USP [1-(o-chloro-α,α- diphenylbenzyl) imidazole], a synthetic antifungal agent, for topical use in the mouth. Structural Formula: C H ClN The troche dosage form is a large, slowly dissolving tablet (lozenge) containing 10 mg of clotrimazole USP dispersed in croscarmellose sodium, dextrates, magnesium stearate, microcrystalline cellulose and povidone. CLINICAL PHARMACOLOGY Clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by altering the permeability of cell membranes. The action of clotrimazole is fungistatic at concentrations of drug up to 20 mcg/mL and may be fungicidal _in vitro_ against _Candida albicans_ and other species of the genus _Candida_ at higher concentrations. No single-step or multiple-step resistance to clotrimazole has developed during successive passages of _Candida albicans_ in the laboratory; however, individual organism tolerance has been observed during successive passages in the laboratory. Such _in vitro_ tolerance has resolved once the organism has been removed from the antifungal environment. After oral administration of a 10 mg clotrimazole troche to healthy volunteers, concentrations sufficient to inhibit most species of _Candida_ persist in saliva for up to three hours following the approximately 30 minutes needed for a troche to dissolve. The long term persistence of drug in saliva appears to be related to the slow release of clotrimazole from the oral mucosa to which the drug is apparently bound. Repetitive dosing at three hour intervals maintains salivary levels above the minimum inhibitory concentrations of most strains of _Candida_; however, the relationship between _in vitro_ susceptibility of pathogenic fungi to clotrimazole and prophylaxis or cure of infections in humans has not been established. In another study, the Lestu allt skjalið